{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:02:07Z","timestamp":1785722527431,"version":"3.56.0"},"reference-count":44,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>To compare the risk of severe adverse pregnancy complications in women with preexisting diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESEARCH DESIGN AND METHODS<\/jats:title><jats:p>Multinational, prospective cohort study to assess the prevalence of newborns free from major congenital malformations or perinatal or neonatal death (primary end point) following treatment with insulin detemir (detemir) versus other basal insulins.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Of 1,457 women included, 727 received detemir and 730 received other basal insulins. The prevalence of newborns free from major congenital malformations or perinatal or neonatal death was similar between detemir (97.0%) and other basal insulins (95.5%) (crude risk difference 0.015 [95% CI \u22120.01, 0.04]; adjusted risk difference \u22120.003 [95% CI \u22120.03, 0.03]). The crude prevalence of one or more congenital malformations (major plus minor) was 9.4% vs. 12.6%, with a similar risk difference before (\u22120.032 [95% CI \u22120.064, 0.000]) and after (\u22120.036 [95% CI \u20130.081, 0.009]) adjustment for confounders. Crude data showed lower maternal HbA1c during the first trimester (6.5% vs. 6.7% [48 vs. 50 mmol\/mol]; estimated mean difference \u22120.181 [95% CI \u22120.300, \u22120.062]) and the second trimester (6.1% vs. 6.3% [43 vs. 45 mmol\/mol]; \u22120.139 [95% CI \u22120.232, \u22120.046]) and a lower prevalence of major hypoglycemia (6.0% vs. 9.0%; risk difference \u22120.030 [95% CI \u22120.058, \u22120.002]), preeclampsia (6.4% vs. 10.0%; \u22120.036 [95% CI \u22120.064, \u22120.007]), and stillbirth (0.4% vs. 1.8%; \u22120.013 [95% CI \u22120.024, \u22120.002]) with detemir compared with other basal insulins. However, differences were not significant postadjustment.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Insulin detemir was associated with a similar risk to other basal insulins of major congenital malformations, perinatal or neonatal death, hypoglycemia, preeclampsia, and stillbirth.<\/jats:p><\/jats:sec>","DOI":"10.2337\/dc21-0472","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T15:20:15Z","timestamp":1627658415000},"page":"2069-2077","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":25,"title":["Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study"],"prefix":"10.2337","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct01892319","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3279-0863","authenticated-orcid":false,"given":"Elisabeth R.","family":"Mathiesen","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norsiah","family":"Ali","sequence":"additional","affiliation":[{"name":"Masjid Tanah Health Clinic, Malacca, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amra C.","family":"Alibegovic","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Anastasiou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology-Diabetes Center, Princess Alexandra Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Cypryk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Diabetology, Medical University of \u0141\u00f3d\u017a, \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"de Valk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Centre Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Dores","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Centro Hospitalar e Universit\u00e1rio do Porto, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidelma","family":"Dunne","sequence":"additional","affiliation":[{"name":"College of Medicine Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari-Anne","family":"Gall","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago Duran","family":"Garcia","sequence":"additional","affiliation":[{"name":"Endo-Diabesidad Cl\u00ednica Dur\u00e1n & Asociados, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne P.","family":"Hanaire","sequence":"additional","affiliation":[{"name":"Department of Diabetology, Metabolic Diseases and Nutrition, University Hospital of Toulouse, University of Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte N.","family":"Husemoen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Ivani\u0161evi\u0107","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, State Referral Center for Diabetes in Pregnancy, Clinical Hospital Center Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Kempe","sequence":"additional","affiliation":[{"name":"Centre for Diabetes and Nutrition Ludwigshafen, Ludwigshafen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"McCance","sequence":"additional","affiliation":[{"name":"Metabolic Unit, Royal Victoria Hospital, Belfast, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Damm","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Obstetrics, Center for Pregnant Women with Diabetes, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"key":"2022031309560041100_B1","unstructured":"International Diabetes Federation . IDF Diabetes Atlas, 9th edition, 2019. Accessed 12 November 2020. Available from: https:\/\/www.diabetesatlas.org\/"},{"key":"2022031309560041100_B2","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2337\/dc09-0656","article-title":"Obstetric and perinatal outcomes in type 1 diabetic pregnancies: a large, population-based study","volume":"32","author":"Persson","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031309560041100_B3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3109\/00016349.2010.518594","article-title":"Congenital anomalies in newborns of women with type 1 diabetes: nationwide population-based study in Norway, 1999\u20132004","volume":"89","author":"Eidem","year":"2010","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2022031309560041100_B4","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s00125-011-2281-7","article-title":"Perinatal and infant mortality in term and preterm births among women with type 1 diabetes","volume":"54","author":"Eidem","year":"2011","journal-title":"Diabetologia"},{"key":"2022031309560041100_B5","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.2337\/diacare.27.12.2819","article-title":"Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study","volume":"27","author":"Jensen","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031309560041100_B6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/bmj.38856.692986.AE","article-title":"Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study","volume":"333","author":"Macintosh","year":"2006","journal-title":"BMJ"},{"key":"2022031309560041100_B7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bpobgyn.2010.11.001","article-title":"Stillbirth in diabetic pregnancies","volume":"25","author":"Mathiesen","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2022031309560041100_B8","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3109\/14767058.2013.794214","article-title":"Pregnancy in women with type 1 diabetes: have the goals of St. Vincent declaration been met concerning foetal and neonatal complications?","volume":"26","author":"Colstrup","year":"2013","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022031309560041100_B9","first-page":"1081","article-title":"Diabetes and pregnancy: national trends over a 15 year period","volume":"61","author":"Mackin","year":"2018","journal-title":"Diabetologia"},{"key":"2022031309560041100_B10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.diabres.2013.10.012","article-title":"Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization Guideline","volume":"103","author":"World Health Organization","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031309560041100_B11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s001250050010","article-title":"Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus","volume":"43","author":"Suhonen","year":"2000","journal-title":"Diabetologia"},{"key":"2022031309560041100_B12","first-page":"814","article-title":"[Insulin detemir (Levemir)]","volume":"60","author":"Scheen","year":"2005","journal-title":"Rev Med Liege"},{"key":"2022031309560041100_B13","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1345\/aph.1E334","article-title":"Insulin detemir--a new basal insulin analog","volume":"39","author":"Goldman-Levine","year":"2005","journal-title":"Ann Pharmacother"},{"key":"2022031309560041100_B14","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diabetes.53.6.1614","article-title":"Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes","volume":"53","author":"Heise","year":"2004","journal-title":"Diabetes"},{"key":"2022031309560041100_B15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1463-1326.2006.00685.x","article-title":"Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes","volume":"9","author":"Klein","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"2022031309560041100_B16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","article-title":"Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis","volume":"81","author":"Monami","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031309560041100_B17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1463-1326.2008.00976.x","article-title":"Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis","volume":"11","author":"Monami","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2022031309560041100_B18","unstructured":"Novo Nordisk . Levemir Summary of Product Characteristics. Accessed 12 November 2020. Available from http:\/\/www.novonordiskmedical.com\/our-products\/levemir.html"},{"key":"2022031309560041100_B19","unstructured":"Sanofi . Lantus Summary of Product Characteristics. Accessed 12 November 2020. Available from https:\/\/products.sanofi.us\/lantus\/lantus.html"},{"key":"2022031309560041100_B20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/dmrr.1213","article-title":"Basal insulin analogues in diabetic pregnancy: a literature review and baseline results of a randomised, controlled trial in type 1 diabetes","volume":"27","author":"Mathiesen","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031309560041100_B21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/dmrr.2730","article-title":"Insulin analogues in pregnancy and specific congenital anomalies: a literature review","volume":"32","author":"de Jong","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031309560041100_B22","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.2337\/dc11-2264","article-title":"Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes","volume":"35","author":"Mathiesen","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031309560041100_B23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/14767058.2013.799650","article-title":"A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes","volume":"27","author":"Hod","year":"2014","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022031309560041100_B24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2337\/diabetes.49.6.999","article-title":"Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use","volume":"49","author":"Kurtzhals","year":"2000","journal-title":"Diabetes"},{"key":"2022031309560041100_B25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12884-016-1177-4","article-title":"Design and rationale of a large, international, prospective cohort study to evaluate the occurrence of malformations and perinatal\/neonatal death using insulin detemir in pregnant women with diabetes in comparison with other long-acting insulins","volume":"17","author":"Mathiesen","year":"2017","journal-title":"BMC Pregnancy Childbirth"},{"key":"2022031309560041100_B26","unstructured":"EUROCAT Central Registry . EUROCAT Guide 1.3 and reference documents: Instructions for the Registration and Surveillance of Congenital Anomalies, 2005. Accessed 12 November 2020. Available from https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/EUROCAT-Guide-1.3.pdf"},{"key":"2022031309560041100_B27","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1002\/(SICI)1097-0258(19981130)17:22<2635::AID-SIM954>3.0.CO;2-C","article-title":"Improved confidence intervals for the difference between binomial proportions based on paired data","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"2022031309560041100_B28","first-page":"CD011880","article-title":"Different insulin types and regimens for pregnant women with pre-existing diabetes","volume":"2","author":"O\u2019Neill","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031309560041100_B29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/14767058.2012.743523","article-title":"Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycaemic control and pregnancy outcome","volume":"26","author":"Callesen","year":"2013","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2022031309560041100_B30","doi-asserted-by":"crossref","first-page":"e014972","DOI":"10.1136\/bmjopen-2016-014972","article-title":"Insulin analogues use in pregnancy among women with pregestational diabetes mellitus and risk of congenital anomaly: a retrospective population-based cohort study","volume":"8","author":"Wang","year":"2018","journal-title":"BMJ Open"},{"key":"2022031309560041100_B31","first-page":"CD007950","article-title":"Effects and safety of periconceptional oral folate supplementation for preventing birth defects","volume":"12","author":"De-Regil","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2022031309560041100_B32","unstructured":"National Institute for Health and Care Excellence . NICE guideline [NG3]: Diabetes in pregnancy: management from preconception to the postnatal period, 2015. Accessed 12 March 2019. Available from https:\/\/www.nice.org.uk\/guidance\/ng3"},{"key":"2022031309560041100_B33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/jcph.616","article-title":"Folic acid supplementation for pregnant women and those planning pregnancy: 2015 update","volume":"56","author":"Chitayat","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2022031309560041100_B34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrendo.2012.154","article-title":"Managing type 1 diabetes mellitus in pregnancy--from planning to breastfeeding","volume":"8","author":"Ringholm","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2022031309560041100_B35","first-page":"276","article-title":"The risks associated with obesity in pregnancy","volume":"115","author":"Stubert","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"2022031309560041100_B36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.metabol.2017.11.011","article-title":"Hypertensive complications of pregnancy: a clinical overview","volume":"86","author":"Antza","year":"2018","journal-title":"Metabolism"},{"key":"2022031309560041100_B37","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00404-015-3741-y","article-title":"Thyroid diseases in pregnancy: a current and controversial topic on diagnosis and treatment over the past 20 years","volume":"292","author":"Giacobbe","year":"2015","journal-title":"Arch Gynecol Obstet"},{"key":"2022031309560041100_B38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12884-019-2572-4","article-title":"Prevalence of self-reported mental disorders in pregnancy and associations with adverse neonatal outcomes: a population-based cross-sectional study","volume":"9","author":"Mongan","year":"2019","journal-title":"BMC Pregnancy Childbirth"},{"key":"2022031309560041100_B39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.chest.2017.08.029","article-title":"Asthma outcomes and management during pregnancy","volume":"153","author":"Bonham","year":"2018","journal-title":"Chest"},{"key":"2022031309560041100_B40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/bdrb.20238","article-title":"Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns","volume":"89","author":"Nakhai-Pour","year":"2010","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"2022031309560041100_B41","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/1471-0528.14026","article-title":"Risk of congenital anomalies after exposure to asthma medication in the first trimester of pregnancy - a cohort linkage study","volume":"123","author":"Garne","year":"2016","journal-title":"BJOG"},{"key":"2022031309560041100_B42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.seizure.2015.02.019","article-title":"Major congenital malformations in children of women with epilepsy","volume":"28","author":"Tomson","year":"2015","journal-title":"Seizure"},{"key":"2022031309560041100_B43","doi-asserted-by":"crossref","first-page":"e013372","DOI":"10.1136\/bmjopen-2016-013372","article-title":"Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort","volume":"7","author":"B\u00e9rard","year":"2017","journal-title":"BMJ Open"},{"key":"2022031309560041100_B44","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.2215\/CJN.00920112","article-title":"Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment","volume":"7","author":"Mathiesen","year":"2012","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/9\/2069\/633238\/dc210472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/9\/2069\/633238\/dc210472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T18:03:40Z","timestamp":1699293820000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/44\/9\/2069\/138853\/Risk-of-Major-Congenital-Malformations-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,8,26]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc21-0472","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]}}}